Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
CARMIEL, Israel, March 15, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018 at 8:30 am Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City.
A live and archived webcast of the presentation will be available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.
Investor Contact
Marcy Nanus, Managing Director
Solebury Trout Group
646-378-2927
[email protected]
